Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The KN510713 Study in Combination With mFOLFIRINOX — Stella

Home/Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)/The KN510713 Study in Combination With mFOLFIRINOX

View on ClinicalTrials.gov

Recruiting

Back to Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) trials

The KN510713 Study in Combination With mFOLFIRINOX

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

South Korea

National Cancer Center, Goyang-si

Key details

Phase

Early testing / Safety & dosing

Sponsor

New Cancer Cure-Bio Co.,Ltd.

Enrollment target

~30 participants

Started

December 2025

Primary completion

September 2028

Age range

19 Years – 75 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.